UK markets closed

Synlogic, Inc. (0A8U.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
2.1250+0.2730 (+14.74%)
At close: 03:08PM GMT
Full screen
Previous close1.8520
Open0.0000
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.0000 - 0.0000
52-week range
Volume6,800
Avg. volume740
Market capN/A
Beta (5Y monthly)1.21
PE ratio (TTM)N/A
EPS (TTM)-0.9740
Earnings date27 Mar 2024 - 01 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Synlogic Adopts Limited Duration Stockholders Rights Plan

    Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review processCAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today announced that its Board of Directors (the “Board”) has approved the adoption of a limited duration shareholder rights plan (the "Rights Plan") and authorized a dividend distribution of one right ("Right

  • GlobeNewswire

    Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update

    Decision to end trial follows internal review of initial data indicating study unlikely to meet primary endpoint Data review found treatment to be safe and well-tolerated Board of Directors plans to perform assessment of strategic options CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, announced today the decision to discontinue Synpheny-3, its ongoing pivotal st

  • GlobeNewswire

    Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

    Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study SYNB1353 was well-tolerated, with similar proportions in both the placebo and active arms reporting mild-moderate gastrointestinal adverse events CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the